Marios Georgakis: GLP-1 Receptor Agonism as a Promising Approach for cSVD
Marios Georgakis, Research Group Leader and Physician at LMU Munich, Visiting Scientist at Broad Institute of MIT and Harvard University, shared on LinkedIn about a recent article he and his colleagues co-authored, adding:
”In our new paper, we leverage human genetic data to provide support for GLP-1 receptor agonism as a promising approach for lowering the burden of cerebral small vessel disease (cSVD).
cSVD is a major unmet need in neurology with no available disease-modifying therapies.
It is a devastating and common aging-related pathology that is associated with stroke, dementia, functional decline, and mortality.
Given the strong efficacy of GLP-1 receptor agonists in reducing atherosclerotic cardiovascular disease, and the known impact of diabetes and obesity on the microvasculature, we explored if human genetic data support for their repurposing for cSVD.
Using genetic variants in the GLP1R locus that mimicked the HbA1c- or BMI-lowering effects of GLP-1 receptor agonists, we ran drug target Mendelian randomization and found associations with
- Lower risk of lacunar (or small vessel) stroke, a clinical cSVD manifestation
- Lower volume of white matter hyperintensities, the most widely used imaging biomarker of cSVD.
These findings provide human genetic support for evaluating GLP-1 receptor agonists in clinical trials targeting cSVD.”
Title: Genetically Simulated GLP-1 Receptor Agonism and Cerebral Small Vessel Disease
Authors: Panagiotis Zangas, Murad Omarov, Marios K. Georgakis
Read the Full Article on Neurology Genetics
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 29, 2026, 03:53Nahrwan Masaoodi: Iron Deficiency Can Exist Without Anemia
-
Sep 29, 2026, 03:38Muhammad Yousaf: Iron Deficiency Beyond Diet
-
Sep 29, 2026, 03:21Parvez Ahmed Chowdhury: Synthesizing Aspirin in the Organic Chemistry Lab
-
Sep 29, 2026, 03:12Ahmed Hamandi: Building the Future of Hematopoietic Transplantation in Iraq
-
Sep 29, 2026, 03:09M V Chandrakanth: Aspirin in CRC – Old Drug, New Precision Oncology?
-
Sep 29, 2026, 03:07Caroline Pothet: Advancing Treatment Development in Sickle Cell Disease and Thalassaemia
-
Sep 29, 2026, 02:53Astha Jain: Thalassemia Care Through a Public Health Lens
-
Sep 29, 2026, 02:50Emma Groarke: Starting a New Career Path in Homeland
-
Sep 28, 2026, 19:14Aditya Sharma: An Outstanding Start to the Final Day of VSS 2026!